Miao Kang, Zhang Li
Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dongcheng District, Beijing 100005, China.
Chin Med J Pulm Crit Care Med. 2023 Sep 13;1(4):215-222. doi: 10.1016/j.pccm.2023.08.002. eCollection 2023 Dec.
Immune checkpoint inhibitors (ICIs) are a class of antitumor medications that target immune checkpoints, which induce the activation of lymphocytes. These treatments effectively prolong the survival of patients with advanced tumors, especially lung cancer. However, in addition to tumor killing effects, ICIs may also cause an imbalance between immune tolerance and immunity. Over-activated lymphocytes may cause various types of damage to multiple organs throughout the body, called immune-related adverse events. In this review, we summarize the pathogenesis, pathological characteristics, biomarkers, and therapeutic agents for immune-related adverse events.
免疫检查点抑制剂（ICIs）是一类靶向免疫检查点的抗肿瘤药物，可诱导淋巴细胞活化。这些治疗有效地延长了晚期肿瘤患者尤其是肺癌患者的生存期。然而，除了杀伤肿瘤的作用外，ICIs还可能导致免疫耐受与免疫之间的失衡。过度活化的淋巴细胞可能会对全身多个器官造成各种类型的损害，即免疫相关不良事件。在本综述中，我们总结了免疫相关不良事件的发病机制、病理特征、生物标志物和治疗药物。
